Nailya R. Makhmudova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nailya R. Makhmudova has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Irina N. Falynskova
ФГБНУ «Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова
5 shared publications - Aleksandr Ermolaev
Pirogov Russian National Research Medical University
3 shared publications - Alexander V. Gurov
Pirogov Russian National Research Medical University
3 shared publications - Tatyana Kleonikovna Dubovaya
Pirogov Russian National Research Medical University
3 shared publications - Z. V. Murzakhanova
Pirogov Russian National Research Medical University
3 shared publications - A. Kh. Dombalagyan
Pirogov Russian National Research Medical University
2 shared publications
Latest Publications
- Open Access
- 4 May 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 7,p. 46-51
Current possibilities of using silver proteinate in the treatment of inflammatory diseases of the nose and paranasal sinuses
The article evaluates the possibility of using silver proteinate to treat acute inflammatory diseases of the nasal cavity and paranasal sinus mucosa, as well as their complications. Acute rhinitis and rhinosinusitis are among the most common upper respiratory diseases. Viral pathogens are the main agents that trigger the pathological process. At the same time, the bacterial superinfection in some cases may develop due to viral infection, which promotes further development of lingering clinical symptoms up to a complicated course of the disease. The course of rhinosinusitis with underlying COVID-19 infection can be complicated by fungal superinfection and postnasal drip. For these reasons, topical drugs that could be used in the early stages of these conditions should have a number of properties, such as activity against most respiratory viruses and aetiologically significant bacterial pathogens; lack of opportunity to evolute and implement rapid resistance mechanisms in microorganisms; additive effects with other antibacterial drugs; acceleration of regeneration of the nasal cavity and paranasal sinus mucosa with underlying infectious alteration; vasoconstrictive and anti-inflammatory action, without causing an addictive effect, which enables repeated use of the drug in chronic diseases, as well as the absence of local and systemic toxic effects. Sialor (silver proteinate) has all the specified characteristics that were proved in various studies, and consistently demonstrated high clinical efficacy for many years.
- 4 May 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 7,p. 46-51
Open AccessCurrent possibilities of using silver proteinate in the treatment of inflammatory diseases of the nose and paranasal sinuses
The article evaluates the possibility of using silver proteinate to treat acute inflammatory diseases of the nasal cavity and paranasal sinus mucosa, as well as their complications. Acute rhinitis and rhinosinusitis are among the most common upper respiratory diseases. Viral pathogens are the main agents that trigger the pathological process. At the same time, the bacterial superinfection in some cases may develop due to viral infection, which promotes further development of lingering clinical symptoms up to a complicated course of the disease. The course of rhinosinusitis with underlying COVID-19 infection can be complicated by fungal superinfection and postnasal drip. For these reasons, topical drugs that could be used in the early stages of these conditions should have a number of properties, such as activity against most respiratory viruses and aetiologically significant bacterial pathogens; lack of opportunity to evolute and implement rapid resistance mechanisms in microorganisms; additive effects with other antibacterial drugs; acceleration of regeneration of the nasal cavity and paranasal sinus mucosa with underlying infectious alteration; vasoconstrictive and anti-inflammatory action, without causing an addictive effect, which enables repeated use of the drug in chronic diseases, as well as the absence of local and systemic toxic effects. Sialor (silver proteinate) has all the specified characteristics that were proved in various studies, and consistently demonstrated high clinical efficacy for many years.
- Open Access
- 13 August 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 14,p. 235-240-240
Indicators of proliferation and antiapoptosis in palatine tonsils in chronic tonsillitis
Introduction. The immune function of the palatine tonsils is associated with a constant proliferation of lymphocytes, therefore, the indicators of proliferation, apoptosis and anti-apoptotic activity in the palatine tonsils are quite informative for assessing their functional state and contribution to adaptive immunity. Chronic inflammation in the palatine tonsils affects their functional state. Understanding the immunocompetence of the palatine tonsils at different stages of the course of chronic tonsillitis allows the optimal tactics of treating this disease, including timely tonsillectomy.Objective. Based on the results of research and literature sources, to find a comparative characteristic of the contribution of palatine tonsils to adequate immunity, ways to assess their proliferative and anti-apoptotic activity.Materials and methods. The study included 158 patients with various forms of chronic tonsillitis and 8 patients without signs of chronic tonsillitis, who were divided into 4 study groups, in accordance with the clinical classification of chronic tonsillitis according to B.S. Preobrazhensky and V.T. Palchun. The tissue samples of the palatine tonsils obtained from patients were examined immunohistochemically in an automatic mode using markers of Ki67 proliferation and Bcl2 antiapoptosis.Results. When conducting an immunohistochemical study with markers of proliferation and anti-apoptosis, an increase in the proliferative and anti-apoptotic activity of lymphoid tissue cells in chronic tonsillitis of a simple form was revealed, and a significant decrease in these indicators in chronic tonsillitis of toxic-allergic forms of I and II stage.Conclusions. Data were obtained on the planned tonsillectomy in chronic tonsillitis of the toxic-allergic form of II degree, as well as in case of ineffectiveness of conservative therapy of tonsillitis of toxic-allergic form of I degree.
- 13 August 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 14,p. 235-240-240
Open AccessIndicators of proliferation and antiapoptosis in palatine tonsils in chronic tonsillitis
Introduction. The immune function of the palatine tonsils is associated with a constant proliferation of lymphocytes, therefore, the indicators of proliferation, apoptosis and anti-apoptotic activity in the palatine tonsils are quite informative for assessing their functional state and contribution to adaptive immunity. Chronic inflammation in the palatine tonsils affects their functional state. Understanding the immunocompetence of the palatine tonsils at different stages of the course of chronic tonsillitis allows the optimal tactics of treating this disease, including timely tonsillectomy.Objective. Based on the results of research and literature sources, to find a comparative characteristic of the contribution of palatine tonsils to adequate immunity, ways to assess their proliferative and anti-apoptotic activity.Materials and methods. The study included 158 patients with various forms of chronic tonsillitis and 8 patients without signs of chronic tonsillitis, who were divided into 4 study groups, in accordance with the clinical classification of chronic tonsillitis according to B.S. Preobrazhensky and V.T. Palchun. The tissue samples of the palatine tonsils obtained from patients were examined immunohistochemically in an automatic mode using markers of Ki67 proliferation and Bcl2 antiapoptosis.Results. When conducting an immunohistochemical study with markers of proliferation and anti-apoptosis, an increase in the proliferative and anti-apoptotic activity of lymphoid tissue cells in chronic tonsillitis of a simple form was revealed, and a significant decrease in these indicators in chronic tonsillitis of toxic-allergic forms of I and II stage.Conclusions. Data were obtained on the planned tonsillectomy in chronic tonsillitis of the toxic-allergic form of II degree, as well as in case of ineffectiveness of conservative therapy of tonsillitis of toxic-allergic form of I degree.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 87 (5) , 43-49
Possibilities of modern forms of antimicrobial peptides in the treatment of inflammatory pathology of the pharynx
Воспалительные заболевания глотки занимают одно из ведущих мест в структуре оториноларингологической патологии. С острыми и хроническими воспалительными процессами в глотке, а также с обострениями последних сталкиваются врачи широкого круга специальностей. Для определения конкретного патогена необходимо лабораторное исследование мазка из ротоглотки, которое требует времени. В связи с этим особый интерес представляют местные лекарственные препараты, обладающие необходимым спектром действия, применение которых возможно в качестве монотерапии или в сочетании с системной терапией. Комбинация тиротрицина (tyrothricin), бензалкония хлорида (benzalkonium chloride) и бензокаина (benzocaine) (доритрицин) обладает высокой эффективностью в лечении бактериальных, вирусных и грибковых поражений глотки, а микроорганизмы стабильно демонстрируют высокую чувствительность к компонентам препарата.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 87 (5) , 43-49
Possibilities of modern forms of antimicrobial peptides in the treatment of inflammatory pathology of the pharynx
Воспалительные заболевания глотки занимают одно из ведущих мест в структуре оториноларингологической патологии. С острыми и хроническими воспалительными процессами в глотке, а также с обострениями последних сталкиваются врачи широкого круга специальностей. Для определения конкретного патогена необходимо лабораторное исследование мазка из ротоглотки, которое требует времени. В связи с этим особый интерес представляют местные лекарственные препараты, обладающие необходимым спектром действия, применение которых возможно в качестве монотерапии или в сочетании с системной терапией. Комбинация тиротрицина (tyrothricin), бензалкония хлорида (benzalkonium chloride) и бензокаина (benzocaine) (доритрицин) обладает высокой эффективностью в лечении бактериальных, вирусных и грибковых поражений глотки, а микроорганизмы стабильно демонстрируют высокую чувствительность к компонентам препарата.
- Open Access
- 13 December 2019
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 96 (6) , 30-39
The safety of attenuated and recombinant nasal influenza vaccines in terms of the development of secondary bacterial superinfection
Introduction. Influenza is a severe viral disease. The most common post-influenza complication is pneumonia. Earlier, we developed an experimental mouse model of viralbacterial pneumonia induced by successive infection with influenza virus and St. aureus, in which lethal synergy between pathogens observed in epidemiological observations was detected.Aim. To study the effect of the administration of intranasal vaccines, followed by infection with St. pneumoniae on the development and completion of the disease.Materials and methods. The animals were immunized intranasal with a strain of attenuated cold-adapted live influenza vaccine A/17/California/2009/38 (H1N1)pdm09 (LAIV) and a recombinant vaccine based on virus-like particles HA(Puerto Rico/8/34)- Gag (VLPs). Control groups of animals were infected with virulent strains of influenza virus A/ California/04/2009 (H1N1)pdm09 or A/Puerto Rico /8/34 (H1N1). On the fifth day after intranasal immunization with the vaccine preparations and infection with pathogenic strains, animals were subjected to bacterial infection with a strain of St. pneumoniae. The presence of synergism of vaccine or viral agent with bacterial infection was assessed by survival and weight loss of animals, virus titer and density of bacteria in nasopharyngeal washes and lungs.Results. It was shown that immunization with vaccine preparations did not lead to increased sensitivity of mice to bacterial infection. Elimination of bacteria from the lungs and nasopharynx in groups immunized with vaccine preparations corresponded to the dynamics in the group of animals immunized by PBS.Discussion. The results obtained indicate the safety of intranasal immunization with LAIV A/17/California/2009/38 (H1N1)pdm09 and virus-like particles HA (Puerto Rico/8/34)- Gag (VLPs) in terms of enhancing secondary bacterial superinfection caused by St. pneumoniae.Conclusion. The studied vaccines successfully blocked infections in the lower respiratory tract.
- 13 December 2019
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 96 (6) , 30-39
Open AccessThe safety of attenuated and recombinant nasal influenza vaccines in terms of the development of secondary bacterial superinfection
Introduction. Influenza is a severe viral disease. The most common post-influenza complication is pneumonia. Earlier, we developed an experimental mouse model of viralbacterial pneumonia induced by successive infection with influenza virus and St. aureus, in which lethal synergy between pathogens observed in epidemiological observations was detected.Aim. To study the effect of the administration of intranasal vaccines, followed by infection with St. pneumoniae on the development and completion of the disease.Materials and methods. The animals were immunized intranasal with a strain of attenuated cold-adapted live influenza vaccine A/17/California/2009/38 (H1N1)pdm09 (LAIV) and a recombinant vaccine based on virus-like particles HA(Puerto Rico/8/34)- Gag (VLPs). Control groups of animals were infected with virulent strains of influenza virus A/ California/04/2009 (H1N1)pdm09 or A/Puerto Rico /8/34 (H1N1). On the fifth day after intranasal immunization with the vaccine preparations and infection with pathogenic strains, animals were subjected to bacterial infection with a strain of St. pneumoniae. The presence of synergism of vaccine or viral agent with bacterial infection was assessed by survival and weight loss of animals, virus titer and density of bacteria in nasopharyngeal washes and lungs.Results. It was shown that immunization with vaccine preparations did not lead to increased sensitivity of mice to bacterial infection. Elimination of bacteria from the lungs and nasopharynx in groups immunized with vaccine preparations corresponded to the dynamics in the group of animals immunized by PBS.Discussion. The results obtained indicate the safety of intranasal immunization with LAIV A/17/California/2009/38 (H1N1)pdm09 and virus-like particles HA (Puerto Rico/8/34)- Gag (VLPs) in terms of enhancing secondary bacterial superinfection caused by St. pneumoniae.Conclusion. The studied vaccines successfully blocked infections in the lower respiratory tract.
- 15 November 2018
- Published by Wiley in Journal of Medical Virology
- Vol. 91 (4) , 588-597
Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study
Antiviral drugs can play a significant role in the control of influenza. Umifenovir (Arbidol) is licensed and widely used in Russia for the prophylaxis and/or treatment of influenza. We evaluated the susceptibility to umifenovir of reference influenza A and B viruses and influenza A viruses isolated from patients in the ARBITR clinical trial in 2012‐2014 seasons. Using an MDCK cell‐based enzyme‐linked immunosorbent assay (ELISA), we showed that the replication of antigenically dominant human influenza A and B viruses was efficiently inhibited by umifenovir. The wild‐type А/Perth/265/2009 (H1N1)pdm09, A/Fukui/45/2004 (H3N2), and B/Perth/211/2001 viruses and their oseltamivir‐resistant counterparts were susceptible to umifenovir among in vitro laboratory assays. All 18 clinical isolates of influenza A viruses obtained before and during therapy were susceptible to umifenovir with 50% effective concentration (EC 50) ranging from 8.4 ± 1.1 to 17.4 ± 5.4 µM. No molecular markers of umifenovir resistance were identified in influenza viruses isolate d from patients at 3, 5, and 7 days after initiation of therapy. None of the viruses isolated before and during umifenovir therapy displayed reduced susceptibility to neuraminidase (NA) inhibitors. Thus, umifenovir is effective against influenza viruses circulating in 2012‐2014 seasons, and therapy did not lead to the emergence of drug‐resistant variants.
- 15 November 2018
- Published by Wiley in Journal of Medical Virology
- Vol. 91 (4) , 588-597
Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study
Antiviral drugs can play a significant role in the control of influenza. Umifenovir (Arbidol) is licensed and widely used in Russia for the prophylaxis and/or treatment of influenza. We evaluated the susceptibility to umifenovir of reference influenza A and B viruses and influenza A viruses isolated from patients in the ARBITR clinical trial in 2012‐2014 seasons. Using an MDCK cell‐based enzyme‐linked immunosorbent assay (ELISA), we showed that the replication of antigenically dominant human influenza A and B viruses was efficiently inhibited by umifenovir. The wild‐type А/Perth/265/2009 (H1N1)pdm09, A/Fukui/45/2004 (H3N2), and B/Perth/211/2001 viruses and their oseltamivir‐resistant counterparts were susceptible to umifenovir among in vitro laboratory assays. All 18 clinical isolates of influenza A viruses obtained before and during therapy were susceptible to umifenovir with 50% effective concentration (EC 50) ranging from 8.4 ± 1.1 to 17.4 ± 5.4 µM. No molecular markers of umifenovir resistance were identified in influenza viruses isolate d from patients at 3, 5, and 7 days after initiation of therapy. None of the viruses isolated before and during umifenovir therapy displayed reduced susceptibility to neuraminidase (NA) inhibitors. Thus, umifenovir is effective against influenza viruses circulating in 2012‐2014 seasons, and therapy did not lead to the emergence of drug‐resistant variants.
- 3 February 2016
- No. 5,p. 32-9
[EFFECTIVENESS OF FULLERENE-(TRIS-AMINOCAPRONIC ACID) HYDRATE IN THE MODEL OF EXPERIMENTAL VIRAL-BACTERIAL PNEUMONIA OF MICE].
Study the effectiveness of the substance and various drug formulations of fullerene-(tris-aminocapronic acid) hydrate (FTAAH onwards) in the model of experimental viral-bacterial pneumonia of mice. BALB/c mice were infected with influenza virus A/California/04/2009 and subsequently infected with Staphylococcus aureus. The animals were treated after viral infection with the substance and various drug forms of FTAAH, as well as comparative preparations--oseltamivir and arbidol. Therapy effectiveness was evaluated by clinical indicators (survival, lifespan, animal mass decrease reduction), virological (virus titer), microbiological (density of bacteria in lungs) parameters, confirmed by pathomorphological characteristics of lungs. FTAAH therapy in injectable form was effective in the model of a combined viral-bacterial pneumonia of mice by all the studied criteria: treatment increased mice survival, reduced the decrease of their body weight, resulted in a reduction of virus titers and density of bacteria in lungs, that correlated with the data from morphological study and signs of bronchopneumonia resolution in mice. FTAAH therapy in rectal form depended on animal infection schemes, as well as preparation dose, increasing with its increase. FTAAH substance is effective in the model of experimental viral-bacterial pneumonia of mice.
- 3 February 2016
- No. 5,p. 32-9
[EFFECTIVENESS OF FULLERENE-(TRIS-AMINOCAPRONIC ACID) HYDRATE IN THE MODEL OF EXPERIMENTAL VIRAL-BACTERIAL PNEUMONIA OF MICE].
Study the effectiveness of the substance and various drug formulations of fullerene-(tris-aminocapronic acid) hydrate (FTAAH onwards) in the model of experimental viral-bacterial pneumonia of mice. BALB/c mice were infected with influenza virus A/California/04/2009 and subsequently infected with Staphylococcus aureus. The animals were treated after viral infection with the substance and various drug forms of FTAAH, as well as comparative preparations--oseltamivir and arbidol. Therapy effectiveness was evaluated by clinical indicators (survival, lifespan, animal mass decrease reduction), virological (virus titer), microbiological (density of bacteria in lungs) parameters, confirmed by pathomorphological characteristics of lungs. FTAAH therapy in injectable form was effective in the model of a combined viral-bacterial pneumonia of mice by all the studied criteria: treatment increased mice survival, reduced the decrease of their body weight, resulted in a reduction of virus titers and density of bacteria in lungs, that correlated with the data from morphological study and signs of bronchopneumonia resolution in mice. FTAAH therapy in rectal form depended on animal infection schemes, as well as preparation dose, increasing with its increase. FTAAH substance is effective in the model of experimental viral-bacterial pneumonia of mice.
- 1 May 2014
- Published by Springer Nature in Pharmaceutical Chemistry Journal
- Vol. 48 (2) , 85-88
Antiviral Activity of Fullerene-(Tris-Aminocaproic Acid) Hydrate Against Respiratory Syncytial Virus in HEp-2 Cell Culture
- 1 May 2014
- Published by Springer Nature in Pharmaceutical Chemistry Journal
- Vol. 48 (2) , 85-88
Antiviral Activity of Fullerene-(Tris-Aminocaproic Acid) Hydrate Against Respiratory Syncytial Virus in HEp-2 Cell Culture
- 1 January 2014
- Vol. 59, 17-24
[Umifenovir (Arbidol) efficacy in experimental mixed viral and bacterial pneumonia of mice].
Pneumonia often occurs as a secondary infection after influenza and accounts for a large proportion of the morbidity and mortality associated with seasonal and pandemic influenza outbreaks. The efficacy of umifenovir (Arbidol) was investigated on a murine model of S. aureus pneumonia following A/California/04/2009 (H1N1) influenza virusinfection. Oral treatment with umifenovir (40 and 60 mg/kg/day) in all the contamination schemes increased the survival rate in the mice from 0% to 90% and lowered the animal weight loss. The umifenovir treatment also decreased the virus titer by ≥ 2 logs and the viable bacteria counts in the lungs of the mice. The lungs of the mice treated with umifenovir had less severe histopathologic lesions compared to the control group.
- 1 January 2014
- Vol. 59, 17-24
[Umifenovir (Arbidol) efficacy in experimental mixed viral and bacterial pneumonia of mice].
Pneumonia often occurs as a secondary infection after influenza and accounts for a large proportion of the morbidity and mortality associated with seasonal and pandemic influenza outbreaks. The efficacy of umifenovir (Arbidol) was investigated on a murine model of S. aureus pneumonia following A/California/04/2009 (H1N1) influenza virusinfection. Oral treatment with umifenovir (40 and 60 mg/kg/day) in all the contamination schemes increased the survival rate in the mice from 0% to 90% and lowered the animal weight loss. The umifenovir treatment also decreased the virus titer by ≥ 2 logs and the viable bacteria counts in the lungs of the mice. The lungs of the mice treated with umifenovir had less severe histopathologic lesions compared to the control group.
- 1 April 2008
- Published by American Society of Parasitologists in Journal of Parasitology
- Vol. 94 (2) , 381-385
Immunostimulating Complexes Incorporating Eimeria tenella Antigens and Plant Saponins as Effective Delivery System for Coccidia Vaccine Immunization
Immunostimulating complexes (ISCOMs) are unique, multimolecular structures formed by encapsulating antigens, lipids, and triterpene saponins of plant origin, and are an effective delivery system for various kinds of antigens. The uses of ISCOMs formulated with saponins from plants collected in Kazakhstan, with antigens from the poultry coccidian parasite Eimeria tenella, were evaluated for their potential use in developing a vaccine for control of avian coccidiosis. Saponins isolated from the plants Aesculus hippocastanum and Glycyrrhiza glabra were partially purified by HPLC. The saponin fractions obtained from HPLC were evaluated for toxicity in chickens and chicken embryos. The HPLC saponin fractions with the least toxicity, compared to a commercial saponin Quil A, were used to assemble ISCOMs. When chicks were immunized with ISCOMs prepared with saponins from Kazakhstan plants and E. tenella antigens, and then challenged with E. tenella oocysts, significant protection was conveyed compared to immunization with antigen alone. The results of this study indicate that ISCOMs formulated with saponins isolated from plants indigenous to Kazakhstan are an effective antigen delivery system which may be successfully used, with low toxicity, for preparation of highly immunogenic coccidia vaccine.
- 1 April 2008
- Published by American Society of Parasitologists in Journal of Parasitology
- Vol. 94 (2) , 381-385
Immunostimulating Complexes Incorporating Eimeria tenella Antigens and Plant Saponins as Effective Delivery System for Coccidia Vaccine Immunization
Immunostimulating complexes (ISCOMs) are unique, multimolecular structures formed by encapsulating antigens, lipids, and triterpene saponins of plant origin, and are an effective delivery system for various kinds of antigens. The uses of ISCOMs formulated with saponins from plants collected in Kazakhstan, with antigens from the poultry coccidian parasite Eimeria tenella, were evaluated for their potential use in developing a vaccine for control of avian coccidiosis. Saponins isolated from the plants Aesculus hippocastanum and Glycyrrhiza glabra were partially purified by HPLC. The saponin fractions obtained from HPLC were evaluated for toxicity in chickens and chicken embryos. The HPLC saponin fractions with the least toxicity, compared to a commercial saponin Quil A, were used to assemble ISCOMs. When chicks were immunized with ISCOMs prepared with saponins from Kazakhstan plants and E. tenella antigens, and then challenged with E. tenella oocysts, significant protection was conveyed compared to immunization with antigen alone. The results of this study indicate that ISCOMs formulated with saponins isolated from plants indigenous to Kazakhstan are an effective antigen delivery system which may be successfully used, with low toxicity, for preparation of highly immunogenic coccidia vaccine.
- 1 August 2005
- Published by Springer Nature in Virus Genes
- Vol. 31 (1) , 13-20
Molecular Characterization of Virulent Newcastle Disease Virus Isolates from Chickens during the 1998 NDV Outbreak in Kazakhstan
Newcastle disease virus (NDV) infects domesticated and wild birds throughout the world and has the possibility to cause outbreaks in chicken flocks in future. To assess the evolutionary characteristics of 10 NDV strains isolated from chickens in Kazakhstan during 1998 we investigated the phylogenetic relationships among these viruses and viruses described previously. For genotyping, fusion (F) gene phylogenetic analysis (nucleotide number 47-421) was performed using sequences of Kazakhstanian isolates as compared to sequences of selected NDV strains from GenBank. Phylogenetic analysis showed that all newly characterized strains belonged to the genetic group designated as VIIb. All strains possessed a virulent fusion cleavage site (RRQRR/F) belonging to velogenic or mesogenic pathotypes with intracerebral pathogenicity indexes (ICPI) varying from 1.05 to 1.87.
- 1 August 2005
- Published by Springer Nature in Virus Genes
- Vol. 31 (1) , 13-20
Molecular Characterization of Virulent Newcastle Disease Virus Isolates from Chickens during the 1998 NDV Outbreak in Kazakhstan
Newcastle disease virus (NDV) infects domesticated and wild birds throughout the world and has the possibility to cause outbreaks in chicken flocks in future. To assess the evolutionary characteristics of 10 NDV strains isolated from chickens in Kazakhstan during 1998 we investigated the phylogenetic relationships among these viruses and viruses described previously. For genotyping, fusion (F) gene phylogenetic analysis (nucleotide number 47-421) was performed using sequences of Kazakhstanian isolates as compared to sequences of selected NDV strains from GenBank. Phylogenetic analysis showed that all newly characterized strains belonged to the genetic group designated as VIIb. All strains possessed a virulent fusion cleavage site (RRQRR/F) belonging to velogenic or mesogenic pathotypes with intracerebral pathogenicity indexes (ICPI) varying from 1.05 to 1.87.